FDA Issues Updated 2026 Regulatory Framework for AI and Machine Learning in Drug and Biologics Submissions
November 16, 2026 • Source: FDA CDER
The US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and CBER published updated 2026 risk-based credibility assessment guidelines for AI/ML models used in IND and BLA submissions.
**Executive Summary (2026-11-16):** The US Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) and CBER published updated 2026 risk-based credibility assessment guidelines for AI/ML models used in IND and BLA submissions. Source: FDA CDER.
Technical Architecture & R&D Impact
Having reviewed over 500 regulatory submissions incorporating AI/ML across target qualification, quantitative systems pharmacology (QSP), digital pathology biomarkers, and CMC process control, the FDA framework defines Context of Use (CoU) validation tiers and 21 CFR Part 11 data provenance requirements.
Enterprise Biopharma Procurement Takeaways
For computational biology leads, medicinal chemists, and R&D IT architects, this milestone underscores the rapid convergence of wet-lab experimental validation and scalable cloud foundation models during H2 2026. Teams evaluating vendors in the Regulation category should benchmark API reproducibility, GxP audit readiness, and zero-data-retention VPC deployment terms.
Related Products
Published November 16, 2026
More NewsLast updated: November 16, 2026
